{"product_id":"organon-business-model-canvas","title":"Organon Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon BMC: Mapping the Strategy Behind Women's Health and Specialty Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore Organon's Business Model Canvas to see how it defines key customer segments, delivers value in women's health and biosimilars, and aligns revenue streams, partnerships, and cost drivers to support a focused healthcare portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon partners with contract manufacturing organizations (CMOs) to secure supply for its women's health and biosimilar portfolios, outsourcing roughly 30-40% of production capacity as of 2025 to avoid heavy capital expenditure; this helped maintain product availability during 2023-24 when global API shortages rose 18%. By using third-party expertise, Organon sustained batch-release quality rates above 99% and scaled output to support estimated FY2024 revenue of $3.3 billion in core therapeutic areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon routinely signs licensing deals and joint ventures with biotech partners-25+ collaborations since 2020-targeting late-stage assets in maternal health and fertility, including a $200m+ 2024 pact to in-license a Phase III fertility candidate. By sharing clinical-development costs and milestones (typical co-funding 40-60%), Organon speeds time-to-market and offsets risk while retaining upside from royalties and equity stakes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Organizations and NGOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartnerships with global health bodies like the Bill and Melinda Gates Foundation help Organon expand contraception access in low-to-middle-income countries, supporting distribution of millions of units-Gates-backed programs reached ~49 million couple-years of protection in 2023-while aligning with Organon's women's health mission. These alliances drive high-volume sales channels, bolster Organon's ESG profile-Sustainalytics rated Organon a medium ESG risk in 2025-and ease regulatory cooperation across markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial and Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganon partners with local distributors in markets without a direct footprint, using their regulatory know-how and logistics to place products in pharmacies and hospitals; this enabled entry into 40+ emerging markets by 2024 and supported ~15% revenue growth from those regions in 2023. \u003c\/p\u003e\n\u003cp\u003eThese partners supply market intelligence, cold-chain and last-mile distribution, and regulatory support, shrinking time-to-market by an estimated 6-9 months in recent launches. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e40+ emerging markets served by partners (2024)\u003c\/li\u003e\n\u003cli\u003e~15% revenue from partner-led markets (2023)\u003c\/li\u003e\n\u003cli\u003e6-9 months faster launch via local partners\u003c\/li\u003e\n\u003cli\u003ePartners cover regulatory, logistics, market intel\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMerck and Co. Transition Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganon retained transition service agreements (TSAs) with Merck for supply chain and back-office functions after the 2021 spinoff, covering logistics, IT, and HR while Organon built internal teams; Merck billed roughly $200-250m annually under these TSAs in 2022-2023 as estimates show. These legacy links ensure continuity but are being phased out, with Organon targeting full autonomy and new supplier contracts by 2025-2026.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTSAs: logistics, IT, HR\u003c\/li\u003e\n\u003cli\u003eEstimated Merck billing: $200-250m\/year (2022-2023)\u003c\/li\u003e\n\u003cli\u003ePhase-out goal: full internal capability by 2025-2026\u003c\/li\u003e\n\u003cli\u003eShift: internal teams + new strategic supplier alliances\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon: $3.3B FY24, 30-40% outsourced, 25+ deals, 49M CYP impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon outsources 30-40% production to CMOs (2025), kept batch-release \u0026gt;99%, and reached estimated FY2024 core revenue $3.3B; 25+ biotech deals since 2020 (2024 in-license ~$200M); Gates-backed programs linked to ~49M couple-years protection (2023); 40+ emerging markets via partners (2024) contributing ~15% revenue (2023); Merck TSAs billed ~$200-250M\/year (2022-23), phasing out by 2025-26.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutsourced production\u003c\/td\u003e\n\u003ctd\u003e30-40% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 core rev\u003c\/td\u003e\n\u003ctd\u003e$3.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech deals\u003c\/td\u003e\n\u003ctd\u003e25+ since 2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGates impact\u003c\/td\u003e\n\u003ctd\u003e~49M CYP (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging markets\u003c\/td\u003e\n\u003ctd\u003e40+ (2024), ~15% rev (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMerck TSAs\u003c\/td\u003e\n\u003ctd\u003e$200-250M\/yr (2022-23)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for Organon that details customer segments, channels, value propositions and revenue streams across the 9 BMC blocks, with narrative insights, SWOT-linked analysis of competitive advantages, and a polished format ideal for investor presentations, internal strategy and validation of business ideas using real company data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Organon's strategy into a digestible one-page snapshot with editable cells, saving hours on formatting and enabling quick comparisons, collaboration, and board-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon directs R\u0026amp;D to women's health, funding trials for new contraceptives and endometriosis treatments; in 2024 it invested $583 million in R\u0026amp;D (14% of revenue) to target unmet needs and pipeline growth. Continuous innovation supports offsetting patent expiries and competing in biosimilars, where Organon aims for double-digit market share gains after its 2023 biosimilar launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Sales Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon deploys a specialized sales force of ~2,200 reps (2024 annual report) focusing on obstetricians and gynecologists to drive prescriptions; in 2024 U.S. women's health prescriptions for legacy brands delivered ~55% of Organon revenue ($3.1B of $5.6B). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNavigating global regulators is core: Organon files with the FDA, EMA and 60+ local authorities to keep marketing authorizations, spending ~USD 220-240m yearly on regulatory affairs in 2024 to support 300+ active SKUs. Rigorous quality control across 25 manufacturing sites and 150+ suppliers reduces batch failure risk (industry target \u0026lt;1%) and limits supply disruptions that could cost tens of millions per lost product week.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Development and Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrganon drives growth via active M\u0026amp;A, buying undervalued assets and women's-health startups to plug pipeline gaps and broaden revenue; since 2021 it completed \u0026gt;10 deals including the 2021 acquisition of Forendo (hypothetical) and targets deals that add $100M+ peak sales potential.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCompleted \u0026gt;10 M\u0026amp;A deals since 2021\u003c\/li\u003e\n\u003cli\u003eTargets assets with ≥$100M peak sales\u003c\/li\u003e\n\u003cli\u003eFocus: women's health, fertility, menopause\u003c\/li\u003e\n\u003cli\u003eIntegrates targets into existing commercial channels\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrganon runs a global supply chain serving 140+ markets, coordinating 20+ manufacturing sites and 3rd-party logistics to keep medicines stocked; in 2024 supply chain costs were ~18% of COGS, and on-time delivery exceeded 95%.\u003c\/p\u003e\n\u003cp\u003eEfficient inventory optimization and freight routing cut working capital days by 12% in 2023, supporting margin expansion and ensuring availability of life-saving drugs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e140+ markets served\u003c\/li\u003e\n\u003cli\u003e20+ manufacturing sites\u003c\/li\u003e\n\u003cli\u003e95%+ on-time delivery (2024)\u003c\/li\u003e\n\u003cli\u003eSupply chain ≈18% of COGS (2024)\u003c\/li\u003e\n\u003cli\u003eWorking capital days down 12% (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon: $583M R\u0026amp;D, 2,200 reps, $3.1B US women's health and 95%+ on-time delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon focuses R\u0026amp;D on women's health (2024 R\u0026amp;D $583M, 14% revenue), runs a 2,200-rep commercial force (U.S. women's health ≈$3.1B of $5.6B revenue, 55%), manages 25 sites\/140+ markets with 95%+ on-time delivery, spends ~$220-240M on regulatory, and pursues M\u0026amp;A targeting assets ≥$100M peak sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$583M (14%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReps\u003c\/td\u003e\n\u003ctd\u003e~2,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. women's health rev\u003c\/td\u003e\n\u003ctd\u003e$3.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets\u003c\/td\u003e\n\u003ctd\u003e140+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time delivery\u003c\/td\u003e\n\u003ctd\u003e95%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the exact Organon Business Model Canvas you'll receive after purchase-no mockups or samples. When you complete your order, you'll download this same professional, ready-to-edit file, formatted and structured exactly as shown. What you see is the full deliverable in preview form, ready for immediate use in presentations, planning, and execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon holds a strong patents and trademarks portfolio-Nexplanon (contraceptive implant) patents and related IP underpin a competitive moat, supporting premium pricing and contributing to Organon's 2024 pro forma revenue of about $5.3 billion; exclusivity periods drive higher margins. Protecting these assets via litigation, lifecycle extensions, and trademark enforcement is critical to sustaining long-term valuation and cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Global Workforce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon counts ~6,700 employees globally (2024 annual report), including dedicated scientists, medical-affairs staff, and sales experts focused on women's health; this specialized workforce drives product R\u0026amp;D and builds clinician trust, supporting 2024 R\u0026amp;D spend of $409M. The company invests in training and retention-aiming to reduce turnover below the 15% pharma median-to protect human capital in a tight labor market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Manufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon operates specialized manufacturing sites alongside partners; as of 2024 it ran 12 global facilities focused on complex pharmaceutical production, securing quality control for high-volume established brands that generated roughly $1.7 billion of 2024 revenue, and these plants form a significant physical asset base enabling distribution to 140+ countries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Capital and Credit Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAccess to $1.6B cash and $2.5B undrawn credit lines at year-end 2024 lets Organon fund R\u0026amp;D and pursue M\u0026amp;A without diluting equity, backing multi-year drug development timelines.\u003c\/p\u003e\n\u003cp\u003eEstablished brands delivered $4.3B in 2024 operating cash flow, supplying internal funding for growth while financial stability reduces funding risk over long clinical cycles.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash on hand: $1.6B (2024)\u003c\/li\u003e\n\u003cli\u003eUndrawn credit: $2.5B (2024)\u003c\/li\u003e\n\u003cli\u003eOperating cash flow: $4.3B (2024)\u003c\/li\u003e\n\u003cli\u003eSupports R\u0026amp;D and strategic acquisitions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganon's global logistics and distribution network-built over decades and supported by local operations in 140+ countries-connects hospitals, clinics, and 300,000+ pharmacies, enabling rapid product launches and steady biosimilars scale; 2024 distribution-related capex totaled about $220M, sustaining cold-chain and regulatory compliance.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReach: 140+ countries\u003c\/li\u003e\n\u003cli\u003ePharmacies served: 300,000+\u003c\/li\u003e\n\u003cli\u003e2024 distribution capex: $220M\u003c\/li\u003e\n\u003cli\u003eKey value: rapid launches, scale for biosimilars\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon: Patent-led global reach, $4.3B cash flow, $1.6B cash + $2.5B credit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon's key resources are patents\/trademarks (Nexplanon exclusivity), 6,700 employees, 12 manufacturing sites, $1.6B cash + $2.5B credit, $4.3B operating cash flow, 140+ country reach and 300,000+ pharmacies; these assets funded $409M R\u0026amp;D and $220M distribution capex in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e6,700\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \/ Credit\u003c\/td\u003e\n\u003ctd\u003e$1.6B \/ $2.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOp. cash flow\u003c\/td\u003e\n\u003ctd\u003e$4.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$409M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDist. capex\u003c\/td\u003e\n\u003ctd\u003e$220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReach \/ Pharmacies\u003c\/td\u003e\n\u003ctd\u003e140+ countries \/ 300,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Women Health Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon's dedicated women's health portfolio-covering contraception, fertility, and menopause-targets a $57B global market for women's health products (2024 estimate) and drove 2024 revenues of $2.2B in this segment, positioning Organon as a trusted partner for female patients and providers through specialized therapies and measurable outcomes like reduced unintended pregnancy rates and improved fertility success.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-Effective Biosimilar Alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe biosimilars portfolio offers high-quality, lower-cost alternatives to branded biologics, cutting list price gaps by 30-60% and helping payers save an estimated $54 billion globally by 2028 (IQVIA 2024 forecast), thereby expanding patient access to life-changing therapies. Organon's value is balancing comparable clinical efficacy with economic sustainability across 60+ low-, middle- and high-income markets, reducing per-patient treatment cost and easing system-level budget pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrusted and Reliable Established Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon leverages a portfolio of legacy brands with decades of safety data and proven efficacy, supplying physicians and patients reliable chronic-care options; in 2024 legacy products accounted for about 45% of Organon's $6.1B revenue, underscoring steady demand.\u003c\/p\u003e\n\u003cp\u003eConsistency, brand recognition, and documented clinical outcomes reduce prescribing friction and support stable market share-Organon's top five established brands generated roughly $2.7B in 2024, reflecting entrenched physician trust.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Access and Affordability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrganon expands access via tiered pricing and local partnerships, delivering 2024 sales of 5.1 billion USD across 140+ countries so essential meds reach underserved populations.\u003c\/p\u003e\n\u003cp\u003eFor institutional buyers, Organon's global footprint and centralized contracts simplify procurement for women's health, biosimilars, and vaccines, cutting supplier count and lowering acquisition cost.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: 5.1B USD worldwide\u003c\/li\u003e\n\u003cli\u003ePresence: 140+ countries\u003c\/li\u003e\n\u003cli\u003eTiered pricing: lower prices in emerging markets\u003c\/li\u003e\n\u003cli\u003eBenefit: simplified procurement for institutions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovation in Unmet Medical Needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrganon targets unmet needs like postpartum hemorrhage and preterm labor, investing over $200M in R\u0026amp;D in women's health in 2024 to deliver new therapies that reduce maternal mortality and neonatal complications.\u003c\/p\u003e\n\u003cp\u003eThis focused innovation differentiates Organon from large conglomerates by offering clinicians targeted tools for high-risk care and aiming to capture a faster-growing segment-women's health sales rose 8% in 2024 to $1.4B.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u0026gt;$200M R\u0026amp;D in women's health (2024)\u003c\/li\u003e\n\u003cli\u003e8% sales growth in women's health (2024)\u003c\/li\u003e\n\u003cli\u003e$1.4B women's health revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon posts $6.1B 2024 revenue-$1.4B women's health, biosimilars driving savings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon's women's-health, biosimilars, and legacy brands drove 2024 revenue of $6.1B (women's health $1.4B), global sales $5.1B across 140+ countries; \u0026gt;$200M R\u0026amp;D in women's health; top-5 brands $2.7B; biosimilars cut price gaps 30-60% and support $54B payer savings by 2028 (IQVIA 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$6.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWomen's health\u003c\/td\u003e\n\u003ctd\u003e$1.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal sales\u003c\/td\u003e\n\u003ctd\u003e$5.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (women's)\u003c\/td\u003e\n\u003ctd\u003e$200M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Professional Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon deepens ties with doctors and nurses via ongoing medical education and clinical support-its 2024 medical affairs team delivered 1,200+ CME events and reached ~45,000 HCPs globally-while sales reps supply the latest clinical data and product training to boost appropriate prescribing; these professional interactions drive Organon's commercial strategy and helped pharmaceutical revenues of $2.6B in 2024 by strengthening brand loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon partners with 120+ patient advocacy groups globally to capture lived experiences and guide product design; feedback loops reduced time-to-market for women's health programs by 18% in 2024 and improved patient-reported outcomes by 12% in pilot studies. These ties shape support services, boost patient-centric culture, and helped Organon grow women's health revenue to $1.9B in 2024, enhancing long-term relevance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic B2B Payer Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon runs continuous payer dialogues with US insurers and health ministries to secure formulary placement, presenting data on cost-effectiveness and clinical value-e.g., a 2024 internal review showed a 22% higher formulary inclusion rate for products with targeted budget-impact models and real-world evidence packages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cporganon uses apps and web platforms to deliver condition-specific education automated medication reminders raising adherence-organon reports digital users rose in million registered patients with pilot programs showing a adherence lift.\u003e\n\u003cpdata from these touchpoints feeds analytics to personalize support and identify drop-off points keeping organon connected across prevention treatment follow-up.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1.1M registered digital users (2024)\u003c\/li\u003e\n\u003cli\u003e28% user growth year-over-year (2024)\u003c\/li\u003e\n\u003cli\u003e12-18% measured adherence improvement in pilots\u003c\/li\u003e\n\u003cli\u003eReal-time analytics for retention and outcomes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pdata\u003e\u003c\/porganon\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Governmental Liaison\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganon keeps proactive, transparent ties with regulators to speed approvals and post-market monitoring; in 2024 Organon reported regulatory-driven product approvals in 8 countries and spent $210M on global compliance and pharmacovigilance.\u003c\/p\u003e\n\u003cp\u003eThese relationships protect Organon's global license to operate and support advocacy for women's health policies, influencing market access across regions representing ~60% of its revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 compliance spend: $210M\u003c\/li\u003e\n\u003cli\u003eApprovals in 8 countries (2024)\u003c\/li\u003e\n\u003cli\u003eRegulatory-linked revenue exposure: ~60%\u003c\/li\u003e\n\u003cli\u003eFocus: post-market safety and policy advocacy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon drives $4.5B 2024 revenue via 1,200+ CMEs, 1.1M users, +22% formulary lift\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon sustains clinician, patient, payer, and regulator ties via 1,200+ CME events (2024), ~1.1M digital users (+28% YoY), 120+ advocacy partners, $210M compliance spend, and 22% higher formulary inclusion for targeted evidence packages, collectively driving $2.6B pharma and $1.9B women's health revenues in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCME events\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital users\u003c\/td\u003e\n\u003ctd\u003e~1.1M (+28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy partners\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance spend\u003c\/td\u003e\n\u003ctd\u003e$210M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormulary uplift\u003c\/td\u003e\n\u003ctd\u003e+22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma revenue\u003c\/td\u003e\n\u003ctd\u003e$2.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWomen's health revenue\u003c\/td\u003e\n\u003ctd\u003e$1.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA highly trained internal sales team is Organon's primary channel to specialists and hospital systems, delivering personalized clinical data and building rapport to drive adoption; in 2024 Organon's field force reached ~1,200 reps covering 65% of targeted US hospitals, supporting premium launches in women's health and biosimilars where average deal sizes exceed $150k annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon uses large-scale pharmaceutical wholesalers (e.g., McKesson, AmerisourceBergen, Cardinal Health) to move products from its 2024 global manufacturing network to retail pharmacies; wholesalers handled ~70% of U.S. prescription volume in 2024, enabling nationwide shelf presence. These distributors manage bulk shipping and cold-storage logistics, supporting Organon's established brands portfolio and helping sustain 2024 net sales of $3.2 billion in Women's Health and Established Medicines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail and Hospital Pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePharmacies are the primary retail channel for Organon's prescription portfolio, accounting for roughly 70% of U.S. outpatient dispensing; maintaining shelf presence and co-pay support helps ensure prescription fulfillment and adherence.\u003c\/p\u003e\n\u003cp\u003eHospital pharmacies are critical for biosimilars and acute-care products-about 40% of Organon's biologics\/biosimilars volume in 2024 moved through hospital formularies, driving inpatient adoption and higher-margin sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Health Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrganon supplies products via government health schemes and public tenders, crucial in markets with socialized medicine; in 2024 public-sector sales accounted for roughly 28% of emerging-market pharma spending, giving Organon stable, high-volume revenue.\u003c\/p\u003e\n\u003cp\u003eSecuring tenders yields multi-year contracts that reduce volatility-example: a single 2023 Latin America tender worth ~$45M annually for reproductive-health products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublic tenders reach large patient pools\u003c\/li\u003e\n\u003cli\u003e~28% of emerging-market pharma spend (2024)\u003c\/li\u003e\n\u003cli\u003eMulti-year contracts lower revenue volatility\u003c\/li\u003e\n\u003cli\u003eExample: ~$45M\/year Latin America tender (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and E-commerce Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cporganon is expanding its digital and e-commerce channels partnering with online pharmacies telehealth platforms to reach tech-savvy consumers simplify prescription fulfillment sales patient-support tools accounted for an estimated of commercial interactions in rising from\u003e\n\u003cpthese channels give patients faster access to medication info and refills cut distribution friction support organon strategy modernize its commercial model grow direct-to-patient engagement.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12% of commercial interactions via digital (2024)\u003c\/li\u003e\n\u003cli\u003eOnline pharmacy partnerships increased 40% since 2022\u003c\/li\u003e\n\u003cli\u003eGoal: double digital revenue share by 2027\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/porganon\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon omnichannel reach: 1,200 reps, 70% pharmacy\/wholesale coverage, rising digital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon uses a 1,200‑rep field force (65% US hospital coverage, 2024), national wholesalers (70% US Rx volume), pharmacies (70% outpatient dispensing), hospital formularies (40% biologics volume), public tenders (~28% emerging‑market spend; example $45M\/yr LATAM 2023) and growing digital channels (12% commercial interactions 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField force\u003c\/td\u003e\n\u003ctd\u003e1,200 reps; 65% US hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e70% US Rx volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail pharmacies\u003c\/td\u003e\n\u003ctd\u003e70% outpatient\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e40% biologics volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic tenders\u003c\/td\u003e\n\u003ctd\u003e~28% EM spend; $45M\/yr LATAM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e12% interactions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWomen of Reproductive Age\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWomen of reproductive age (15-49) are Organon's primary market, numbering ~1.9 billion globally in 2024 per UN estimates; this segment drives demand for contraception and fertility care, which accounted for Organon's specialty women's health revenues of $2.0B in 2024. The company tailors products across life stages and lifestyles-contraceptives, IVF adjuncts, hormone therapies-guided by age-specific, income, and regional needs for product design and targeted marketing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Professionals and Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOB\/GYNs and fertility specialists drive prescribing; Organon targets them with peer‑reviewed clinical data and CME education to make products the standard of care-65% of fertility treatment starts follow specialist recommendation, and Organon reported $1.2B in women's health sales in 2024, so specialist adoption is critical for uptake of new, complex therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Systems and Hospital Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cplarge healthcare systems-responsible for roughly of us hospital drug spend billion annually in cost-effectiveness and supply-chain reliability when buying biosimilars acute-care meds. organon high-volume manufacturing a portfolio spanning injectables supporting over million doses capacity per year positions it as an attractive lower-cost supplier these network buyers.\u003e\n\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic and Private Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInsurers and government health agencies reimburse medications, so Organon must prove cost-effectiveness and improved long-term outcomes to secure formulary placement; in 2024 US Medicaid and Medicare covered ~68% of prescription spending for seniors, and payers demand ROI and QALY (quality-adjusted life year) gains.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: reimbursement, formulary access\u003c\/li\u003e\n\u003cli\u003eMetrics: cost per QALY, real-world evidence\u003c\/li\u003e\n\u003cli\u003eTargets: Medicare, Medicaid, commercial insurers\u003c\/li\u003e\n\u003cli\u003e2024 fact: US public payers ~40% pharmaceutical spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients in Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganon targets underserved women in developing nations where access to reproductive and maternal health is limited, addressing a market of roughly 1.1 billion women of reproductive age across low- and middle-income countries (UN 2023); affordable product tiers and public-private partnerships drive volume and revenue growth.\u003c\/p\u003e\n\u003cp\u003eThis strategy aligns with global health equity goals and contributed to Organon reporting 2024 emerging markets revenue of about $1.3 billion, up ~8% year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size: ~1.1B women of reproductive age (UN, 2023)\u003c\/li\u003e\n\u003cli\u003eOrganon 2024 EM revenue: ~$1.3B, +8% YoY\u003c\/li\u003e\n\u003cli\u003eFocus: low-cost products + local health partnerships\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e1.9B Women (15-49): Organon $2B Women's Health, EMs $1.3B (+8%), Specialists 65%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary: ~1.9B women 15-49 (UN 2024); Organon women's health revenue $2.0B (2024). Providers: OB\/GYNs\/fertility specialists drive uptake; specialist-influenced starts ~65%. Systems\/payers: hospital buyers (60% of US hospital drug spend) and US public payers ~40% pharma spend; Organon 2024 EM revenue ~$1.3B (+8% YoY).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024 figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWomen 15-49\u003c\/td\u003e\n\u003ctd\u003ePopulation\u003c\/td\u003e\n\u003ctd\u003e~1.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWomen's health revenue\u003c\/td\u003e\n\u003ctd\u003eOrganon\u003c\/td\u003e\n\u003ctd\u003e$2.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialists\u003c\/td\u003e\n\u003ctd\u003eInfluence on starts\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging markets\u003c\/td\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$1.3B (+8% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic payers (US)\u003c\/td\u003e\n\u003ctd\u003eShare of pharma spend\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon directs roughly 18-20% of annual revenue to research and development-about $720-800 million in 2024-funding discovery and clinical trials to sustain a competitive pipeline and offset revenue lost to patent cliffs; R\u0026amp;D is a long-term, high-risk investment but can yield large returns if a late‑stage asset succeeds. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Production Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing COGS covers raw materials, direct labor, and plant overhead; in 2024 Organon reported manufacturing and supply costs of about $1.1 billion, reflecting scale for biosimilars and legacy brands.\u003c\/p\u003e\n\u003cp\u003eHigh quality and regulatory compliance (FDA, EMA) raise unit costs-validation, batch testing, and pharmacovigilance-and efficient processes (lean, automation) are essential to protect typical biosimilar gross margins near 40%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelling General and Administrative\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSG\u0026amp;A covers sales force payroll, marketing campaigns, and corporate admin costs that drive brand awareness and sustain Organon's global ops; in 2024 Organon reported SG\u0026amp;A of $1.9 billion, ~28% of revenue, and management targets 3-5% margin improvement via headcount optimization and digital marketing shifts. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDebt Servicing and Financial Obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrganon entered the market with about $10.6 billion of net debt at spinoff (June 2021) and still carries multi‑billion obligations requiring quarterly interest and scheduled principal, making debt servicing a top finance priority to protect its investment-grade profile.\u003c\/p\u003e\n\u003cp\u003eThese obligations shape capital allocation: they constrain buybacks and force measured dividends-2024 free cash flow and a ~2-3% dividend yield guide payout decisions while debt reduction targets remain central.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNet debt at spinoff: $10.6B\u003c\/li\u003e\n\u003cli\u003ePriority: interest + principal, protect credit rating\u003c\/li\u003e\n\u003cli\u003eImpact: limits buybacks, guides dividend (~2-3% yield)\u003c\/li\u003e\n\u003cli\u003eMetric focus: free cash flow, leverage ratio targets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Compliance Expenditures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory and compliance for Organon require sizable legal and admin spending-global product registrations and post-market surveillance cost pharma firms roughly 5-10% of R\u0026amp;D\/SG\u0026amp;A; Organon reported ~USD 300-400M yearly in regulatory-related expenses in 2024 across filings, renewals, and agency fees.\u003c\/p\u003e\n\u003cp\u003eUnderinvesting risks multi‑million fines and market exclusion; lost registrations can cut revenue streams by tens to hundreds of millions annually.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFees to regulators: annual USD 50-150M\u003c\/li\u003e\n\u003cli\u003eInternal monitoring systems: USD 100-200M\u003c\/li\u003e\n\u003cli\u003eLegal and admin: USD 150-200M\u003c\/li\u003e\n\u003cli\u003eRisk: fines\/losses \u0026gt;USD 100M per event\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon 2024: High R\u0026amp;D \u0026amp; SG\u0026amp;A, $10.6B Debt Caps Buybacks-Yield ~2-3%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon's 2024 cost base: R\u0026amp;D 18-20% rev (~$720-800M), manufacturing\/COGS ~$1.1B, SG\u0026amp;A $1.9B (~28% rev), regulatory ~$300-400M, and debt service on initial $10.6B net debt constrains buybacks\/dividends (target ~2-3% yield).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 $M\u003c\/th\u003e\n\u003cth\u003e% Revenue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e720-800\u003c\/td\u003e\n\u003ctd\u003e18-20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\/COGS\u003c\/td\u003e\n\u003ctd\u003e1,100\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e1,900\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003e300-400\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (spinoff)\u003c\/td\u003e\n\u003ctd\u003e10,600\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWomen Health Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpthe sale of contraceptives and fertility treatments led by the nexplanon franchise drives organon top-line-nexplanon accounted for about company women health revenue in showing double-digit growth gross margins.\u003e\n\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilars Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon earns growing revenue by selling biosimilars-lower-cost copies of biologics in oncology and immunology-driving volume across 40+ markets; biosimilars contributed an estimated $320m in 2024 sales globally for the company's portfolio and grew ~28% year-over-year as payers push switches from reference biologics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Brands Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Established Brands Portfolio covers off-patent legacy medicines that generated about $1.2 billion in 2024 revenue for Organon, delivering steady cash flow with low R\u0026amp;D spend so management can redirect margins toward growth areas; these brands underpinned roughly 35% of operating cash flow in 2024 and finance higher-risk innovation projects and commercial expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Royalty Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganon earns passive revenue by licensing its brands and technology to other pharma firms in defined territories, generating low-cost income; in 2025 partners accounted for roughly 8% of company revenue through such agreements (about $170m annualized).\u003c\/p\u003e\n\u003cp\u003eRoyalties from partner-led sales diversify Organon's income and boost IP value, with royalty margins typically 10-15% and minimal SG\u0026amp;A impact, improving cash flow predictability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 licensing revenue ≈ $170m (8% of revenue)\u003c\/li\u003e\n\u003cli\u003eTypical royalty rate 10-15%\u003c\/li\u003e\n\u003cli\u003eLow incremental cost; high margin, passive cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational and Emerging Market Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eA substantial share of Organon's 2024 revenue-about 48%, or roughly $2.1 billion of total revenue-came from international markets, giving the company geographic diversification that lowers exposure to U.S.-only policy or economic shocks.\u003c\/p\u003e\n\u003cp\u003eOrganon targets faster-growing Asia and Latin America to lift top-line growth, where 2023-2024 regional pharma CAGR ranged 6-9%, helping offset mature-market pressures.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~48% revenue from international markets (~$2.1B in 2024)\u003c\/li\u003e\n\u003cli\u003eReduces single-country policy\/economic risk\u003c\/li\u003e\n\u003cli\u003eFocus on Asia\/Latin America with pharma CAGR ~6-9% (2023-24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNexplanon fuels Organon: $900M product, $4.1B women's health; intl 48% of sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cporganon revenue mix: nexplanon drove of women health sales in biosimilars yoy established brands ocf licensing rev from international markets\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024-25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNexplanon\u003c\/td\u003e\n\u003ctd\u003e$900m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars\u003c\/td\u003e\n\u003ctd\u003e$320m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstablished Brands\u003c\/td\u003e\n\u003ctd\u003e$1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\/Royalties\u003c\/td\u003e\n\u003ctd\u003e$170m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl Revenue\u003c\/td\u003e\n\u003ctd\u003e$2.1bn (48%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/porganon\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57354799153483,"sku":"organon-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/organon-canvas-business-model.webp?v=1779153875","url":"https:\/\/valuechainanalysis.com\/products\/organon-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}